Jump to content

Rizatriptan: Difference between revisions

From Pharmacopedia
[unchecked revision][checked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,189 edits
VisualWikitext
Expand stub to full MedTemplate parameter set
parser-claude: Rizatriptan MedTemplate refill, Top 300 stub upgrade
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{MedTemplate
{{MedTemplate
| generic           = Rizatriptan
| generic           = Rizatriptan (benzoate)
| brand             = Maxalt
| brand             = Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet)
| structure         =  
| structure         =
| classes           = Triptan, Migraine medicine
| classes           = [[:Category:Triptans|Triptan (5-HT1B/1D agonist)]], [[:Category:Antimigraine medicines|Antimigraine medicine]], [[:Category:Analgesics|Analgesic]]
| mechanism          = 5-HT1B/1D agonist
| uses             = <vote slug="acute-migraine-use">Acute migraine with or without aura (FDA; adult and pediatric ages 6+)</vote>
| uses               =  
| starting_dose     = 5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours
| starting_dose     =  
| preparations     = Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg
| preparations       =  
| fda_max          = 30 mg/24 hours
| routes            =  
| pill_id           =
| onset              =
| routes            = Oral
| duration           =  
| onset            = 30 minutes for migraine relief
| halflife          =  
| duration         = 4-6 hours; headache recurrence is common
| bioavailability    =  
| halflife          = 2-3 hours<ref name="maxalt-label">FDA Prescribing Information, Maxalt (rizatriptan benzoate), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020864s022,020865s024lbl.pdf</ref>
| pregnancy         =  
| bioavailability   = ~45% (oral; substantially higher than sumatriptan's ~14%)<ref name="maxalt-label" />
| legal              =  
| pregnancy        = Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.{{citation needed}}
| intro              =  
| legal             = [[USLegal:Prescription only|Rx-only]] in US
| pharmacokinetics   =  
| mechanism         = <vote slug="rizatriptan-mech-claim">Selective 5-HT1B and 5-HT1D receptor agonist (the triptan-class signature). Compared to sumatriptan, oral bioavailability is substantially higher (~45% vs ~14%) and onset is faster, with similar headache-recurrence rates. The 5-HT1B effect produces cranial vasoconstriction reversing the neurogenic vasodilation of migraine; the 5-HT1D effect inhibits CGRP release at trigeminal nerve terminals.</vote> '''Propranolol substantially raises rizatriptan exposure''' (~70% increase) via MAO-A inhibition of rizatriptan metabolism; the 5 mg dose is required when used with propranolol. Same triptan-class contraindications: coronary artery disease, vasospastic angina, uncontrolled hypertension, ischemic stroke history, hemiplegic or basilar migraine<ref name="maxalt-label" />.
| pharmacodynamics  =  
| indications        =  
| dosing             =  
| effects            =
| contraindications  =
| interactions      =
| pregnancy_details  =
| monitoring         =  
| counseling        =  
| anecdotes          =
| seealso            =
| references        =  
}}
}}


== References ==
<references />
[[Category:Triptans]]
[[Category:Antimigraine medicines]]
[[Category:Analgesics]]
[[Category:Analgesics]]

Latest revision as of 07:22, 23 May 2026

Triptan (5-HT1B/1D agonist), Antimigraine medicine, Analgesic
Rizatriptan (benzoate)
Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet)

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Triptan (5-HT1B/1D agonist), Antimigraine medicine, Analgesic
Common uses
Acute migraine with or without aura (FDA; adult and pediatric ages 6+)0
Pharmacy
Starting dose
5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours
Preparations
Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg
US FDA Max
30 mg/24 hours
Pharmacology
Routes
Oral
Onset
30 minutes for migraine relief
Duration
4-6 hours; headache recurrence is common
Half-life
2-3 hours[1]
Bioavailability
~45% (oral; substantially higher than sumatriptan's ~14%)[1]
Pregnancy
Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Selective 5-HT1B and 5-HT1D receptor agonist (the triptan-class signature). Compared to sumatriptan, oral bioavailability is substantially higher (~45% vs ~14%) and onset is faster, with similar headache-recurrence rates. The 5-HT1B effect produces cranial vasoconstriction reversing the neurogenic vasodilation of migraine; the 5-HT1D effect inhibits CGRP release at trigeminal nerve terminals.0 Propranolol substantially raises rizatriptan exposure (~70% increase) via MAO-A inhibition of rizatriptan metabolism; the 5 mg dose is required when used with propranolol. Same triptan-class contraindications: coronary artery disease, vasospastic angina, uncontrolled hypertension, ischemic stroke history, hemiplegic or basilar migraine[1].

References

  1. ↑ 1.0 1.1 1.2 FDA Prescribing Information, Maxalt (rizatriptan benzoate), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020864s022,020865s024lbl.pdf
Retrieved from "https://pharmacopedia.wiki/index.php?title=Rizatriptan&oldid=6713"